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Edited by Felix WielandAbstract Sialylation (e.g. expression of sialic acid) plays a cru-
cial role for function and stability of most glycoproteins. The key
enzyme for the biosynthesis of sialic acid is the UDP-N-acetyl-
glucosamine 2-epimerase/N-acetylmannosamine-kinase (GNE).
Mutations in the binding site of the feedback inhibitor CMP-sia-
lic acid of the GNE leads to sialuria, a disease in which patients
produce sialic acid in gram scale. Here, we report on the use in
biotechnology of sialuria-mutated GNE. Expression of the sial-
uria-mutated GNE in CHO-cells leads to increased sialylation
of recombinant expressed erythropoietin (EPO). Our data show
that sialuria-mutated-GNE over-expressing cells are the perfect
platform to express highly sialylated therapeutic proteins, such
as EPO.





The number of recombinant glycoproteins used in therapy
has increased over the past years and many of the high-value
therapeutic proteins in the market today are glycoproteins.
Usually recombinant glycoproteins are produced in mamma-
lian cell lines to obtain mammalian-type glycosylation. This
is a major issue in biotechnology since glycan composition of
recombinant glycoproteins determines their biological func-
tions [1]. The terminal position of N-linked complex glycans
is typically occupied by sialic acid. Presence of sialic acid in-
crease the in vivo circulatory lifetime of glycoproteins as sialic
acid terminated glycans are not recognized by asialoglycopro-
tein receptors of hepatocytes [2–5]. In contrast, unsialylated
glycoproteins are recognized by the asialoglycoprotein recep-
tor via the exposed galactose and targeted for degradation
[6]. However, the sialylation of over-expressed glycoproteins
in mammalian cell lines like Chinese Hamster Ovary (CHO)
cells used for the production of therapeutic glycoproteins is*Corresponding author. Fax: +49 345 5573811.
E-mail address: ruediger.horstkorte@medizin.uni-halle.de (R. Horst-
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doi:10.1016/j.febslet.2007.07.060incomplete [7] and result in an objectionable heterogenic sialyl-
ation of the product.
The biosynthesis of sialic acid is regulated by the feedback
inhibition of the key enzyme of sialic acid biosynthesis, the
UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE) [8]. GNE
is a bifunctional enzyme, which catalyzes the conversion of
UDP-GlcNAc to ManNAc and the phosphorylation of Man-
NAc to ManNAc-6-phosphate (see Fig. 1) [9,10]. The next step
is a condensation of ManNAc-6-P and pyruvat resulting in sia-
lic acid. Then, sialic acid is activated in the nucleus into the
nucleotide donor CMP-sialic acid [11,12]. CMP-sialic acid
inhibits GNE in a feedback dependent manner [13]. Several
approaches have been made to enhance sialylation and to max-
imize the yield of high quality glycoproteins for pharmaceutical
use. It has been suggested that insuﬃcient concentration of
CMP-sialic acid inside the trans-Golgi is the major cause for
incomplete intracellular sialylation in CHO-cells [12]. There-
fore, most approaches focus on an increased concentration of
CMP-sialic acid inside the trans-Golgi. To bypass the feedback
mechanism cells can be supplemented with ManNAc, which
intercept the pathway beyond the GNE (see Fig. 1). The supple-
mentation with ManNAc leads to an increased intracellular
concentration of sialic acid and to an increased sialylation of
recombinant glycoproteins in CHO cells [13]. Also the overex-
pression of the CMP-sialic acid golgi transporter and several
sialyltransferases slightly enhance the sialylation [14,15].
Sialuria is a rare inborn error of the sialic acid metabolism.
A defect of the feedback inhibition is caused by point muta-
tions within the epimerase domain of GNE (R263L, R266Q,
and R266W) leading to excessive synthesis of sialic acid [16].
We have previously shown that the expression of GNE-
R263L led to an increased polysialylation of the neural cell
adhesion molecule (NCAM) [17]. In this article, we will report
on the use of the GNE sialuria mutation to increase intracellu-
lar sialic acid concentration and to improve sialylation of re-
combinant glycoproteins. As a model system we have chosen
CHO-cells producing recombinant human erythropoietin
(rhEPO). EPO is a glycoprotein hormone that is a cytokine
for erythrocyte precursors [18]. It contains three complex type
N-glycans located on Asn residues at position 24, 38 and 83,
and an O-glycosylation site at position 126 [19] and has a max-
imum of 14 sialic acids per molecule (4 sialic acids molecules
on each tetra-antennary N-glycan and 2 sialic acids molecules
on the O-glycans). The sialylation is important for the biolog-
ical activity of EPO. Weak or non-sialylated EPO has a dra-
matically decreased biological activity due to the reduced
circulatory half-life [20,21].ation of European Biochemical Societies.
Fig. 1. Schematic representation of the sialic acid biosynthesis.
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2.1. Generation of stable CHO-EPO cells expressing sialuria mutated
GNE
An GNE-sialuria expression vector, pcDNA3.1-GNE-R263L, were
constructed by inserting the entire rat GNE coding region carrying a
point mutation (CGA to CTA) into the KpnI/HindIII site of the
expression vector pcDNA3.1()zeocin. The pcDNA3.1-GNE-R263L
vector was transfected with Lipofectamin (Invitrogen) into a CHO-
EPO cell line, which were prior transfected with a hEPO expression
vector (pKex-cmvEPO) carrying a hygromycin B resistance and
selected with 400 lg/ml hygromycin B for stable production of high
levels of recombinant human EPO (rhEPO). Stable transfected
CHO-EPO-GNE263L clones were isolated after 6 weeks of selection
with 1 mg/ml zeocin.
2.2. Sialic acid quantiﬁcation
Free sialic acid was quantiﬁed by the periodate/resorcinol method
[22]. In brief, lysates from 20 · 106 cells were oxidized in 250 ll with
5 ll of 0.4 M periodic acid at 37 C for 90 min, followed by 15 min
boiling in 500 ll of 6% resorcinol/2.5 mM CuSO4/44% HCl. After
cooling for a few minutes, 500 ll tert-butyl alcohol were added, the
samples were vortexed and centrifuged for 5 min to precipitate cell
debris. Immediately after spinning, the supernatants were poured into
OD cuvettes and read at 630 nm. Sialic acid concentrations were calcu-
lated by comparison with a standard curve.
2.3. Culture of CHO cells
Cells were cultured at 37 C (5% CO2/air) in tissue culture ﬂasks con-
taining alpha-MEM (Biowest) medium and 10% FCS. Hygromycin B
(200 mg/ml) was added to the CHO-EPO cell line culture. Prior 2D-
electrophoresis analysis cells were adapted to serum free CHO-S-
SFM-II (Gibco) medium.
2.4. 2D-electrophoresis
High resolution 2D electrophoresis was performed according to
O’Farrell [23]. In brief, cells were seeded with a cell count of 106 cells
in 10 cm plates with 5 ml CHO-S-SFM-II (Gibco) medium. After 48 h
a 1 mL aliquot of the medium was taken and desalted and concen-
trated to a volume of 50 ml with 5 K NMWL centrifugal ﬁlters
(Millipore). The 50 ml sample was mixed with 320 ml rehydration buf-
fer (2.4 M thiourea, 8.4 M urea, 4.8% CHAPS, 2.4% Immobiline-buﬀer
from Pharmacia, 0.36% DTT) and used to rehydrate Immobiline
Dry Strips (pH 4–7, 11 cm) for 12 h in a rehydration tray. Therehydrated strip was subjected to isoelectric focusing on a MultiPhorII
electrophoresis chamber at the following voltage gradients: 50 V for
12 h, 250 V for 3 h, 1000 V for 1 h, 10000 V for 5 h, and 10000 V
for 6 h (total 88 kV h). After focusing, the strips were incubated in
equilibration buﬀer (10 ml consisting of 6 M urea, 2% SDS, 0.375 M,
pH 8.8, Tris–HCl, 20% glycerol, bromophenol blue) containing 1%
DTT for 10 min, followed by an incubation with equilibration buﬀer
containing 2.5% iodoacetamide for 10 min. The equilibrated IPG strip
was placed onto a 10% polyacrylamide gel and a SDS–PAGE was per-
formed.
2.5. Immunoblotting
The SDS–polyacrylamide gels were transferred to nitrocellulose
ﬁlters. The blots were blocked with 5% fat-free dry milk powder in
PBS, incubated with the EPO (B4)-monoclonal antibody (Santa Cruz
5290), washed with PBS and incubated with the secondary antibodies
(horseradish peroxidase (HRP) conjugated rabbit anti-mouse). After
washing, proteins were detected by enhanced chemiluminescence
(Amersham Buchler) according to the manufacturer’s instructions,
and visualized by exposing the blots to a Fuji imager system (LAS)
for 2 min.
2.6. Proliferation assay
Cells were seeded in 96-well plates at a cell density of 2 · 104 cells per
well in standard medium and incubated for 24 h. The assay was per-
formed as described by Porstman et al. [24] using the cell proliferation
(BrdU) ELISA kit from Roche Diagnostics according to the instruc-
tion manual. The labeling time with BrdU was 3 h and incubation with
anti-BrdU-peroxidase-antibody was for 2 h. Each experiment was per-
formed in quadruplicates.3. Results and discussion
We transfected CHO-K1 cells with rhEPO, using an expres-
sion vector containing a hygromycin-resistance gene to obtain
a cell line producing EPO as our model recombinant protein.
Among the clones, which acquired hygromycin-resistance,
the clone with the highest EPO-expression (CHO-EPO) was
used for the further experiments. These CHO-EPO cells were
then stably transfected with rat GNE-sialuria (R263L), using
the pcDNA3.1-()-zeocin expression vector. A clonal CHO-
Fig. 2. Concentration of sialic acid in CHO-cells. Wild type CHO cells (WT), CHO cells treated with 10 mM ManNAc for 48 h (M), Clone 1–14 of
stable transfected CHO-EPO-sialuria cells (C1–C14). Sialic acid concentration was measured using the periodate/resorcinol method. Bars represent
mean values ± S.D. of three independent experiments carried out in duplicates.
Fig. 3. Immunodetection of EPO after isoelectric focusing of conditioned medium from CHO-EPO cells, CHO-EPO cells supplemented with 10 mM
ManNAc and CHO-EPO-GNE-sialuria (C5) cells. Every spot represents EPO with a diﬀerent pI and a diﬀerent degree of sialylation.
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dilution. To verify the functionality of the sialuria mutation
the free sialic concentration of 14 selected CHO-EPO-sialuria
clones were quantiﬁed, applying the resorcinol/periodic acid
assay (Fig. 2). While the concentration sialic acid of some
clones were in the range of CHO wild type cells (15 fmol/cell),
the majority of clones even exceed the concentration of CHO
cells fed with 10 mM ManNAc for 48 h (40 fmol/cell). The
highest concentration measured was 90 fmol/cell in clone 5
(Fig. 2, C5). This shows that the introduction of GNE with
a defect in the feedback inhibition increases the concentration
of cellular sialic acid at least 6-fold compared to the wild type
cells. Subsequently we determined if this increase of sialic acid
has any inﬂuence on the degree of sialylation of EPO. Two-
dimensional gel electrophoresis is a common method to study
sialylation of glycoproteins. Due to the negative charge of sia-
lic acid a change in the degree of sialylation will lead to a shift
of the isoelectric point (pI) of the sialylated protein while a
lower pI is representing a higher sialylation. Therefore
we performed an isoelectric focusing with a subsequently
immunoblotting, using an anti-EPO antibody (Fig. 3). EPO
expressed by wild type CHO-cells was detected as a large spot
at pH 4.2 and many further spots between pH 5 and 6, corre-
sponding to diﬀerent pIs and representing the diﬀerent degreesof sialylation of EPO. When the CHO-EPO cells were fed with
10 mM of the sialic acid precursor ManNAc to increase the
sialylation, the heterogeneity of the expressed EPO was mark-
edly reduced. Beside the major spot at pH 4.2 there were only
two minor spots around pH 5 detectable. However, we found a
nearly homogenous sialylation when EPO was expressed by
the CHO-EPO-sialuria-cells. Virtually all EPO was in the high
sialylated form with a pI of 4.2 (Fig. 3). This shows that the
overexpression of GNE-sialuria (R263L) can enhance the
sialylation of rhEPO by increasing the intracellular concentra-
tion of free sialic acid and even lead to a higher sialylation then
in ManNAc supplemented cells. For biotechnology use it is
important that the expression of the GNE-Sialuria (R263L)
did not interfere with the growth rate or viability of the
CHO cells. Therefore, we analyzed the proliferation of the
C5 cells with a standard BrdU-assay (Fig. 4) and found that
the proliferation was nearly unchanged. We measured a reduc-
tion by 6.5% compared to the CHO-EPO cells however an
increase by 9.2% compared to CHO-EPO cells which were
supplemented with 10 mM ManNAc.
Taken together, we generated a novel cell line for the expres-
sion of highly sialylated glycoproteins. Since the production of
recombinant glycoproteins has a growing business volume
of more the 40 billion dollar per year we believe that the use
Fig. 4. BrdU-proliferation assay. CHO-EPO cells, CHO-EPO-sialuria cells or CHO-EPO cells supplemented with 10 mMManNAc were analyzed in
the presence or absence of serum (serum-free CHO-cell expression medium). Induction of DNA synthesis was measured by the incorporation of
pyrimidine analogue 5-bromo-2 0deoxyuridine (BrdU), instead of thymidine, into the DNA of proliferating cells. The cells were incubated with BrdU
for 3 h and the incooperation of BrdU into the DNA was detected by immunoassay. At least two experiments were performed in quadruplicates.
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